Product image of Metoprolol Onkogen (Metoprolol Tartrate) supplied by GNH India

Metoprolol Onkogen

Active Ingredient:
Metoprolol Tartrate
Origin:
EU

Metoprolol Onkogen (Metoprolol Tartrate)

Metoprolol Tartrate, the active ingredient in Metoprolol Onkogen, is a beta‑adrenergic receptor blocker presented as an intravenous solution for intravenous use. It treats hypertension, angina pectoris, acute myocardial infarction, chronic heart failure and cardiac arrhythmias in adult patients.

GNH India supplies Metoprolol Onkogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Onkogen Kft.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Metoprolol Onkogen, a selective β1‑adrenergic blocker, is used in cardiovascular conditions that involve elevated heart rate or myocardial oxygen demand.

  • Hypertension: reduces systolic and diastolic pressure by decreasing cardiac output and renin release.
  • Angina pectoris: lowers myocardial oxygen demand, relieving chest pain during exertion.
  • Acute myocardial infarction: improves survival by limiting infarct size and reducing arrhythmic risk.
  • Chronic heart failure: enhances ventricular filling and reduces symptomatic congestion.
  • Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other supraventricular tachyarrhythmias.

How It Works

  • Metoprolol Tartrate selectively antagonises β1‑adrenergic receptors on cardiac myocytes, inhibiting catecholamine‑induced stimulation of adenylate cyclase. This reduces intracellular cyclic AMP, leading to decreased calcium influx, slower sino‑atrial node firing, reduced myocardial contractility, and lower heart rate, ultimately diminishing cardiac output and oxygen consumption.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Fatigue: persistent tiredness during therapy.
  • Dizziness: light‑headedness, especially on standing.
  • Bradycardia: heart rate below normal limits.
  • Headache: mild to moderate intensity.

Serious or Rare Side Effects

  • Severe bradycardia: may require medical intervention.
  • Hypotension: marked drop in blood pressure.
  • Heart block: conduction disturbances that can be life‑threatening.
  • Bronchospasm: especially in patients with reactive airway disease.
  • Allergic reactions: rash, urticaria, or anaphylaxis.
  • Cardiogenic shock: profound cardiac failure requiring emergency care.

Precautions & Warnings

Careful monitoring and patient assessment are essential before and during therapy.

  • Monitor blood pressure: check regularly to avoid hypotension.
  • Assess heart rate: watch for bradycardia or excessive slowing.
  • Evaluate respiratory status: caution in patients with asthma or COPD.
  • Review concomitant drugs: avoid combining with other negative‑chronotropic agents without supervision.
  • Adjust in renal impairment: dose may need modification based on renal function.
  • Store at room temperature: keep in original container, protect from light and moisture.

Avoid Interactions

Metoprolol may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

  • Non‑selective beta‑blockers: additive bradycardia and hypotension.
  • Calcium channel blockers (verapamil, diltiazem): profound AV‑node depression.
  • Clonidine withdrawal: rebound hypertension if stopped abruptly.

Moderate Interactions (Monitor Closely)

  • Antidiabetic agents: may mask hypoglycaemia symptoms.
  • NSAIDs: can reduce antihypertensive effect of metoprolol.

Frequently Asked Questions

Metoprolol Onkogen is indicated for the management of hypertension, angina pectoris, acute myocardial infarction, chronic heart failure, and certain cardiac arrhythmias such as atrial fibrillation. It is administered intravenously to achieve rapid cardiovascular control in these settings.

Metoprolol Tartrate selectively blocks β1‑adrenergic receptors in the heart, reducing the effects of adrenaline and noradrenaline. This leads to a slower heart rate, decreased contractility, and lower cardiac output, helping to lower blood pressure and reduce myocardial oxygen demand.

The specific dose of Metoprolol Onkogen is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals adjust the intravenous infusion rate or bolus amount according to clinical guidelines and individual needs.

Safety data for Metoprolol Onkogen in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metoprolol Onkogen is a selective β1‑blocker, offering cardiac‑focused effects with fewer respiratory side effects compared with non‑selective agents like propranolol. Its intravenous formulation provides rapid onset, which is advantageous in acute settings such as myocardial infarction or hypertensive emergencies.

Metoprolol Onkogen should be stored at room temperature, below 25 °C, in its original packaging. Protect the solution from direct light and moisture, and ensure the container is tightly sealed to maintain sterility.

The product is supplied as an intravenous solution and is administered directly into a vein by a qualified healthcare professional. Administration may be as a controlled infusion or a slow intravenous bolus, following the prescriber’s instructions.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in susceptible individuals, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these events, especially during initiation or dose adjustments.

Metoprolol Onkogen is contraindicated in patients with known hypersensitivity to metoprolol or any component of the formulation, those with severe bradycardia, second‑ or third‑degree heart block without a pacemaker, and patients in cardiogenic shock unless under strict medical supervision.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.